Dr. Grothey on Trastuzumab for Gastroesophageal Cancer

Video

Dr. Axel Grothey from the Mayo Clinic on Trastuzumab for Gastroesophageal Cancer

Axel Grothey, MD, Professor of Oncology, Consultant, Medical Oncology, Mayo Clinic, discusses the first-line use of the targeted agent trastuzumab (Herceptin) to treat HER2-positive gastroesophageal cancer.

Trastuzumab is the first targeted agent to be used as a first-line therapy in gastroesophageal cancer. All patients with the disease should now be test for an overexpression of HER2. If patients are HER2-positive trastuzumab should be added to the standard chemotherapy, which is usually 5-fluorouracil and platinum agents such as cisplatin.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,